SCHEMBL6984672

SCHEMBL6984672

CC(Cl)(Cl)C(NC(=O)c1cc(F)cc(F)c1)Nc1c(Nc2cccnc2)c(=O)c1=O

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNJ11 Q14654 11/20 0.53
ABCC9 O60706 10/20 0.53
ABCC8 Q09428 7/20 0.53
KCNJ8 Q15842 7/20 0.53
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPKAPK2 P49137 3/20 0.43
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6987810 0.93 ABCC9 (0.47) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6986346 0.86 MAPKAPK2 (0.45) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6985929 0.86 ABCC9 (0.58) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6988592 0.85 KCNJ11 (0.54) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6989026 0.85 ABCC9 (0.49) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6990454 0.83 ABCC9 (0.52) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6983541 0.81 MAPKAPK2 (0.52) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL7555212 0.81 ABCC9 (0.51) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL6989283 0.81 ABCC9 (0.51) KCNJ11ABCC9ABCC8KCNJ8CYP1A2
SCHEMBL4371299 0.81 PLK1 (0.37) KCNJ11ABCC9ABCC8KCNJ8CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US claimed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US claimed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 KCNJ11 2/4885ABCC9 1043/4885ABCC8 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.